A PHASE IIA STUDY EVALUATING THE SAFETY AND TOLERABILITY OF UMBRALISIB AND IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) - Lunning, M.; Bierman, P.; Bociek, R.; Armitage, J.; Heires, P.; Blumel, S.; Hohenstein, M.; Lyden, L.; Vose, J.